Absci is using its AI-driven discovery platform to design antibodies against “unaddressable” targets (GPCRs, ion channels, difficult-to-agonize targets), citing its Origin-1 model’s ability to ...
The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.
A Body to Live In’ a fascinating trip into a transgressive culture ...
A cornerstone of the platform is a fixed-price model. Lilly is offering the Zepbound KwikPen to network pharmacies at a discounted rate of $449 for all dosages. The final cost to patients will still ...